Replimune Group, Inc. (REPL)
Healthcare • Biotechnology
StockNasdaqGSUnited StatesUS76029N1063
Kyvero is an independent information site. It is not affiliated with, endorsed by or sponsored by Replimune Group, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in USD. Dividends, results and news are marked on the day they happened; click a day to see them.
Updated 12 Nov 2026 20:51. Information, not advice. Showing the last 12 months. Create a free account to see the whole history
Results
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 03 Feb 2027 08:00 | -0.47 | — | — | Upcoming |
| 28 Oct 2026 07:00 | -0.79 | -0.54 | +31.5% | Beat |
| 14 Aug 2026 08:00 | -0.77 | -0.72 | +6.3% | Beat |
| 11 Aug 2026 08:00 | -0.77 | — | — | — |
| 29 Jun 2026 08:00 | -0.72 | -0.76 | -5.6% | Miss |
| 03 Feb 2026 08:00 | -0.82 | -0.77 | +6.5% | Beat |
| 06 Nov 2025 08:00 | -0.79 | -0.90 | -13.5% | Miss |
| 07 Aug 2025 08:00 | -0.80 | -0.95 | -18.7% | Miss |
| 22 May 2025 07:00 | -0.69 | -0.82 | -18.8% | Miss |
| 12 Feb 2025 08:00 | -0.72 | -0.79 | -9.6% | Miss |
| 12 Nov 2024 08:00 | -0.74 | -0.68 | +7.7% | Beat |
| 08 Aug 2024 08:00 | -0.83 | -0.78 | +6.6% | Beat |
| 16 May 2024 08:00 | -0.80 | -0.25 | +68.6% | Beat |
| 08 Feb 2024 08:00 | -0.93 | -0.77 | +17.7% | Beat |
| 07 Nov 2023 08:00 | -0.89 | -0.90 | -0.8% | In line |
| 03 Aug 2023 08:00 | -0.84 | -0.75 | +10.7% | Beat |
| 18 May 2023 08:00 | -0.66 | -0.74 | -12.1% | Miss |
| 09 Feb 2023 08:00 | -0.74 | -0.69 | +7.1% | Beat |
| 03 Nov 2022 08:00 | -0.76 | -0.79 | -4.0% | Miss |
| 04 Aug 2022 08:00 | -0.56 | -0.78 | -38.8% | Miss |
| 19 May 2022 08:00 | -0.60 | -0.60 | -0.8% | In line |
| 03 Feb 2022 08:00 | -0.57 | -0.57 | +0.2% | In line |
| 04 Nov 2021 08:00 | -0.52 | -0.56 | -7.5% | Miss |
| 06 Aug 2021 08:00 | -0.42 | -0.53 | -26.3% | Miss |
| 20 May 2021 08:00 | -0.38 | -0.41 | -6.9% | Miss |
| 04 Feb 2021 08:00 | -0.41 | -0.42 | -3.2% | Miss |
| 05 Nov 2020 08:00 | -0.44 | -0.46 | -5.4% | Miss |
| 07 Aug 2020 07:00 | -0.43 | -0.44 | -1.3% | Miss |
| 03 Jun 2020 07:00 | -0.43 | -0.41 | +5.7% | Beat |
| 13 Feb 2020 07:00 | -0.36 | -0.46 | -26.6% | Miss |
| 11 Nov 2019 08:00 | -0.34 | -0.35 | -3.7% | Miss |
| 14 Aug 2019 08:00 | -0.31 | -0.30 | +4.0% | Beat |
| 28 Jun 2019 08:00 | -0.42 | -0.15 | +64.1% | Beat |
| 14 Feb 2019 08:00 | -0.25 | -0.24 | +2.1% | Beat |
| 14 Nov 2018 08:00 | -0.19 | -0.26 | -33.3% | Miss |
| 30 Aug 2018 09:00 | -0.21 | -0.42 | -98.1% | Miss |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2026 | 0 | — | -313.9M | — | -3.38 | -10.1% | -284.6M |
| 2025 | 0 | — | -247.3M | — | -3.07 | +5.2% | -198.9M |
| 2024 | 0 | — | -215.8M | — | -3.24 | -8.4% | -191.1M |
| 2023 | 0 | — | -174.3M | — | -2.99 | — | -130.3M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 12 Nov 2026 | 21.32 | 22.08 | 20.48 | 21.93 | +0.71% | 2,150,889 | |
| 11 Nov 2026 | 23.54 | 23.54 | 21.74 | 21.78 | -6.44% | 3,031,100 | |
| 10 Nov 2026 | 22.10 | 23.41 | 22.00 | 23.28 | +4.58% | 3,017,300 | |
| 09 Nov 2026 | 21.90 | 22.72 | 21.75 | 22.26 | +2.96% | 3,204,300 | |
| 06 Nov 2026 | 20.20 | 21.91 | 20.20 | 21.62 | +7.99% | 2,972,200 | |
| 05 Nov 2026 | 20.57 | 20.59 | 19.33 | 20.02 | -3.24% | 3,998,200 | |
| 04 Nov 2026 | 20.80 | 21.15 | 20.21 | 20.69 | +0.19% | 3,215,000 | |
| 03 Nov 2026 | 19.52 | 21.26 | 19.50 | 20.65 | +5.95% | 4,728,600 | |
| 02 Nov 2026 | 17.75 | 19.67 | 17.67 | 19.49 | +10.68% | 7,722,700 | |
| 30 Oct 2026 | 17.49 | 18.27 | 16.64 | 17.61 | +1.27% | 3,852,400 | |
| 1,245 older periods: create a free account to see the whole history | |||||||
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- REPL Stock Up 80% in a Month on Tudriqev Launch & Pipeline Progress (opens in a new tab) Zacks · 12 Nov 2026 14:44
- How Investors May Respond To Replimune Group (REPL) Narrower Quarterly Loss (opens in a new tab) Simply Wall St. · 05 Nov 2026 08:19
- Wall Street Analysts Believe Replimune Group (REPL) Could Rally 26.8%: Here's is How to Trade (opens in a new tab) Zacks · 02 Nov 2026 13:55
- Replimune Soars 17% as TUDRIQEV Melanoma Launch Draws “Enthusiastic” Response From Physicians (opens in a new tab) TIKR · 29 Oct 2026 18:41
- Why Did ETSY, REPL, GMAB Stocks Surge To 52-Week Highs Today? (opens in a new tab) Stocktwits · 29 Oct 2026 03:07
- Is Replimune Group (REPL) Cheap Following Its Reduced Net Loss Results? (opens in a new tab) Simply Wall St. · 29 Oct 2026 02:07
- Replimune: 3 Key Takeaways for Long-Term Investors (opens in a new tab) Motley Fool · 29 Oct 2026 01:33
- Replimune Group, Inc. Q2 2027 Earnings Call Summary (opens in a new tab) Moby · 29 Oct 2026 00:35
- Replimune (REPL) Q2 2027 Earnings Call Transcript (opens in a new tab) Motley Fool · 28 Oct 2026 22:44
- Replimune Group (REPL) Stock Looks Rich After A 141% Run (opens in a new tab) Simply Wall St. · 17 Oct 2026 17:14
- Replimune Group (REPL) Launches TUDRIQEV As Its Valuation Story Comes Into Focus (opens in a new tab) Simply Wall St. · 09 Oct 2026 16:12
- Why Did SJM, REPL, NEO Stocks Surge To 52-Week Highs Today? (opens in a new tab) Stocktwits · 27 Aug 2026 04:13
Headlines link to the original articles of the publishers shown; Kyvero does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 21.78 USD
- Market cap
- 2.1B
- Exchange
- NasdaqGS
- Country
- United States
- Sector
- Healthcare
- Industry
- Biotechnology
- Currency
- USD
Dividends
No dividends on record.
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Business growth Yearly growth of revenue and of earnings per share. | 8.8 / 25 No figures for this part: it counts as a cautious 35%. | — |
| Quality Return on equity, net margin and how stable the margins are. | 0.0 / 25 |
|
| Financial strength Net debt against operating earnings, interest cover and free cash flow. | 0.0 / 20 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 0.0 / 15 | — |
| Analysts How far the analysts' average target is from today's price. | 5.5 / 10 |
|
- Score capped at 50: three or more warnings
- Thin interest cover: operating profit is only -35.9× the interest
- The last full year was a loss
- Total debt has risen three years in a row
Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 70% of the figures (grade C). Warnings take 18 points off.
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio. How the score works
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| P/E (forward) | -32.76× | Weak | 14.16× |
| Price / book | 10.18× | Weak | 3.5× |
| EV / EBITDA | -7.17× | Weak | 11.19× |
| Free cash flow yield | -7.1% | Weak | 2.1% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 0% | Weak | 54.9% |
| Operating margin | 0% | Weak | 5.8% |
| Net margin | 0% | Weak | 1.2% |
| Return on equity | -115.8% | Weak | 4.4% |
| Return on assets | -43.9% | Weak | 2.7% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | 0.62× | Good | 0.4× |
| Interest cover | -35.93× | Weak | 2.17× |
| Current ratio | 7.11× | Good | 2.64× |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Similar shares
Follow REPL and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.